Yeast and bacteria combination for the best of both worlds Yeast and bacteria have been successfully used as probiotic for decades: bacteria, mainly from the Lactobacilli and Bifidobacteria species; and yeast Saccharomyces cerevisiae var. […]
Azitra, Inc. (NYSE American: AZTR) (the “Company”), a biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products, today announced the closing of its initial public offering of […]
In a study by a research group at Baylor College of Medicine, oral administration of a commercially available probiotic bacterial strain was found to improve dry eye disease in an animal model. The findings were […]
Metagen Therapeutics, a company focusing on drug discovery and development based on intestinal microbiome-based therapeutics for various diseases, has completed its Series A funding in 2 rounds, raising a total of 1.7 billion yen. Sparx […]
Verb Biotics LLC., a microbiome innovation company, today announced that they have acquired YSOPIA Bioscience’s strain and IP portfolio targeted for human health and wellness. The acquisition of YSOPIA’s strain portfolio includes one of the […]
APC Microbiome Ireland, a world-leading SFI research centre based at UCC (University College Cork), has joined forces with BowelScreen and the Mater Misericordiae University Hospital, as part of 8 partner organisations from 5 European countries […]
TargEDys and Biocodex have been partners since 2019, when Biocodex became a shareholder and board member of TargEDys. Soon after, Biocodex became the distributor of TargEDys’ leading PreciBiomic, Symbiosys Satylia®, in France, then in Portugal […]
Seres Therapeutics, Inc. (Nasdaq: MCRB) and Nestlé Health Science today announced that VOWST™ (fecal microbiota spores, live-brpk) is now commercially available for patients. VOWST, formerly called SER-109, is the first and only U.S. Food and Drug […]
Complicated, hard-to-heal wounds are a growing medical problem and there are currently only two drugs approved with proven efficacy. In a new study on humans, researchers at Uppsala University show that treatment with a specific […]
Abstract Microbiome drug development has captured significant interest over the last decade. However, despite the recent clinical and regulatory success stories, this area is lately regarded as a high-risk one by investors given the current […]
Original Source: Sandwalk Bioventures The Spanish Medicines Agency (AEMPS) just authorized its first-ever drug based on live microorganisms for vaginal application. Muvagyn®, containing live L. gasseri and L. rhamnosus, is indicated for the normalisation of […]